Proteome Sciences

  • was founded in 1994 and has over 25 years of experience; our proteomic services being fully aligned to your drug development pipeline.
  • invented, developed and now exclusively manufacture TMT 11-plex and newer TMTpro 16-plex and more recently 18-plex isobaric tags. These are supplied to other Mass Spectrometer users globally via our distribution partner ThermoFisher as part of their Mass Spectrometry consumable range.
  • is a specialised Contract Research Organisation (CRO) offering a full suite of Mass Spectrometric based protein discovery and detection tools on an outsourced client driven basis.
  • has worked with the majority of the top biopharma organisation globally and are ideally suited become your proteomic analysis partner.
  • handles all sample types including biological fluids and tissue from a variety of animal and plant sources.
  • covers the full needs from research and clinical via Discovery and Targeted workflows utilising Thermo Fisher Orbitrap, and TSQ Vantage triple quad mass spectrometers depending on the application.
  • works under ISO 9001:2015 for Discovery based Applications and Good Clinical Laboratory Practice (GCLP) for Targeted Assays as required.
  • offers a complete CRO Proteomic Discovery and Targeted based analytical service …
    • incoming sample QC check
    • sample preparation
    • full proteome characterisation,
    • dedicated bioinformatics data interpretation and
    • comprehensive analytical report
    • additional Post Translational Modified searches and biological interpretation (on request)

Our services are broken down as follows:

Contact us for a free initial discussion and price estimate on your project.

Contact us for an example copy of our final analysis report.

Recent news

May 16, 2024

Result of Annual General Meeting (AGM)

The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 12.00 noon today, all resolutions were duly passed.
May 16, 2024

Annual General Meeting Statement

Annual General Meeting Statement
April 26, 2024

Substantial contract for Proteome Sciences

Proteome Sciences (AIM:PRM), is pleased to announce that the Company has secured a contract win from a US biopharmaceutical company using the Company’s mass spectrometry services for the analysis of samples for an on-going clinical trial.
April 10, 2024

Final results for the year ended 31 December 2023

The Company is pleased to announce its audited results for the year ended 31 December 2023.
January 2, 2024

Completion of new facility in San Diego

Proteome Sciences is pleased to announce the completion of installation and setup of equipment in its new US laboratory in San Diego, California. and is therefore now fully operational. 
November 30, 2023

Trading update for the year 2023

The Company announces a trading update to its shareholders.

Recent Updates

Keep up to date with proteome sciences and learn about crucial areas about our services and scientists
Applied Proteomics

Detailed measurement of proteins from samples collected during drug development & clinical research to inform better decision making and outcomes

  • Biomarker Services Outsource partner for proteomics and biomarker assays. Significant investment in MS knowledge and instrumentation
  • Reagents for mass spectrometry Exclusive TMT licence with Thermo Scientific
  • Bioinformatics Data insights and analyses
  • Proprietary Licences / IP Portfolio of >400 patents across range of diseases and applications

Upcoming events